Overview
ACHV market data
Price History
ACHV price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.25 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.28 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.37 – $7.11 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $642.6 · P/B 12.30 · P/S 36.06.
Company news
Phoenix Education Partners, Pentair And Other Big Stocks Moving Lower In Wednesday’s Pre-Market SessionBenzinga · Jul 15, 2026, 12:02 PM
8-K filing — ACHIEVE LIFE SCIENCES, INC. (ACHV)SEC EDGAR · Jul 6, 2026, 8:06 PM
Achieve Life Sciences Added To Russell 2000 Index, Effective June 26Benzinga · Jun 29, 2026, 12:45 PM
FDA Declines To Approve Achieve Life Sciences' Smoking Cessation Drug; Q4 Resubmission PlannedBenzinga · Jun 22, 2026, 3:45 PM
HC Wainwright & Co. Reiterates Buy on Achieve Life Sciences, Maintains $12 Price TargetBenzinga · Jun 22, 2026, 3:35 PM
Achieve Life Sciences Receives FDA's Complete Response Letter Regarding New Drug Application For Cytisinicline; FDA Identifies No Deficiencies Regarding Clinical Efficacy, Safety Of CytisiniclineBenzinga · Jun 22, 2026, 12:35 PM